EA201391453A1 - Новое антитело против рецептора il-23 человека - Google Patents

Новое антитело против рецептора il-23 человека

Info

Publication number
EA201391453A1
EA201391453A1 EA201391453A EA201391453A EA201391453A1 EA 201391453 A1 EA201391453 A1 EA 201391453A1 EA 201391453 A EA201391453 A EA 201391453A EA 201391453 A EA201391453 A EA 201391453A EA 201391453 A1 EA201391453 A1 EA 201391453A1
Authority
EA
Eurasian Patent Office
Prior art keywords
against human
antibody against
receptor
antibody
new antibody
Prior art date
Application number
EA201391453A
Other languages
English (en)
Other versions
EA026119B1 (ru
Inventor
Макото Охори
Таканори Сасаки
Хирому Сато
Кацунари Тагути
Original Assignee
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк.
Publication of EA201391453A1 publication Critical patent/EA201391453A1/ru
Publication of EA026119B1 publication Critical patent/EA026119B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Задачей настоящего изобретения является получение антитела против IL-23R человека, обладающего превосходной активностью и/или перекрестной реактивностью по сравнению с обычно применяемыми антителами против IL-23R, и средство для использования антитела для профилактики или лечения различных заболеваний, в патогенез которых вовлечен IL-23R человека. Средство для решения: антитело против IL-23R человека, содержащее вариабельную область тяжелой цепи, состоящую из аминокислотной последовательности SEQ ID NO:5, 9, 13, 17, 21, 25 или 29, и вариабельную область легкой цепи, состоящую из аминокислотной последовательности SEQ ID NO:7, 11, 15, 19, 23, 27 или 31.
EA201391453A 2011-04-01 2012-03-30 Новое антитело против рецептора il-23 человека EA026119B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011081982 2011-04-01
PCT/JP2012/058531 WO2012137676A1 (ja) 2011-04-01 2012-03-30 新規抗ヒトｉｌ－２３受容体抗体

Publications (2)

Publication Number Publication Date
EA201391453A1 true EA201391453A1 (ru) 2014-01-30
EA026119B1 EA026119B1 (ru) 2017-03-31

Family

ID=46969077

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391453A EA026119B1 (ru) 2011-04-01 2012-03-30 Новое антитело против рецептора il-23 человека

Country Status (16)

Country Link
US (1) US9556276B2 (ru)
EP (1) EP2695897B1 (ru)
JP (1) JP5971238B2 (ru)
KR (1) KR20140032392A (ru)
CN (2) CN103459426B (ru)
AR (1) AR085824A1 (ru)
BR (1) BR112013024923A2 (ru)
CA (1) CA2831751A1 (ru)
EA (1) EA026119B1 (ru)
ES (1) ES2728438T3 (ru)
MX (1) MX347955B (ru)
PL (1) PL2695897T3 (ru)
PT (1) PT2695897T (ru)
TR (1) TR201908197T4 (ru)
TW (1) TW201249867A (ru)
WO (1) WO2012137676A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2821416T (pt) * 2012-02-28 2018-12-14 Astellas Pharma Inc Anticorpo de recetor il-23 anti- humano inovador
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
JP6987072B2 (ja) * 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド アクチビン２型受容体結合タンパク質及びその使用
CN111471655B (zh) * 2020-03-19 2023-07-07 湖州正熙医学检验实验室有限公司 抗人il12/23稳转细胞株及其构建方法和应用
CN113698484B (zh) * 2021-10-13 2023-07-18 浙江博锐生物制药有限公司 抗il-23r抗体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0690132B1 (en) 1993-03-11 2003-12-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-hiv monoclonal antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2395025A1 (en) * 2007-02-28 2011-12-14 Schering Corporation Engineered Anti-IL-23R Antibodies
WO2010027767A1 (en) 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
CA2741566A1 (en) * 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment

Also Published As

Publication number Publication date
EP2695897A9 (en) 2015-10-07
JPWO2012137676A1 (ja) 2014-07-28
CN104817641A (zh) 2015-08-05
CN103459426A (zh) 2013-12-18
EP2695897A1 (en) 2014-02-12
CN104817641B (zh) 2018-06-26
EP2695897B1 (en) 2019-05-01
JP5971238B2 (ja) 2016-08-17
MX2013011414A (es) 2014-04-14
US9556276B2 (en) 2017-01-31
EP2695897A4 (en) 2015-03-18
AR085824A1 (es) 2013-10-30
KR20140032392A (ko) 2014-03-14
EA026119B1 (ru) 2017-03-31
WO2012137676A1 (ja) 2012-10-11
CA2831751A1 (en) 2012-10-11
MX347955B (es) 2017-05-16
US20140275490A1 (en) 2014-09-18
PL2695897T3 (pl) 2019-08-30
PT2695897T (pt) 2019-06-12
TW201249867A (en) 2012-12-16
TR201908197T4 (tr) 2019-06-21
ES2728438T3 (es) 2019-10-24
BR112013024923A2 (pt) 2016-11-22
CN103459426B (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
NZ706377A (en) Il-6 antagonists and uses thereof
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
NZ610734A (en) Human antibodies to the glucagon receptor
NZ703653A (en) Anti-fap antibodies and methods of use
RU2017129721A (ru) АНТИТЕЛА ПРОТИВ αβTCR
CY1118551T1 (el) Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
EA201490433A1 (ru) Новое антитело против ngf человека
CY1121678T1 (el) Νεο αντισωμα εναντι του ανθρωπινου υποδοχεα tslp
TN2014000513A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
PE20170687A1 (es) Proteinas de enlace a cd127
NZ594682A (en) Fully human antibodies specific to cadm1
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
EA201492163A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU